|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
675     |
  Yesterday |
508     |
  Since 2006 |
1,945,798     |
|
|
|
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
Industry : |
| |
Pharmaceutical |
| | |
Product : |
| |
Drug nanosuspension |
| | |
Test Objective : |
| |
Solvent / antisolvent crystallization |
| | |
Reactants : |
| |
Drug solution and water - reactant streams are miscible |
| | |
Processor : |
| |
Microfluidics reactors     (Microfluidizer High Shear Processor Àåºñº¸±â) |
| | |
Chambers : |
| |
Interaction Chamber (upstream) F20Y (75 um)
Auxiliary Processing Module (downstream) H30Z (200 um) |
| | |
Number of passes : |
| |
1 - 3 |
| | |
Median particle size : |
| |
D50 = 480 nm |
| | |
Process pressure : |
| |
12,000 psi |
| | |
Summary of results : |
| |
As a drug solution interacted with an anti-solvent, the drug precipitated in the form of nanocrystals.
(pdf ÈÀÏ ´Ù¿î·Îµå) |
| | |
| |   |
| |   |
| |
|
|
  |
|
|
|
| | |
|
|
|